Discovery of 1-Hydroxypyridine-2(1H)-thione-6-carboxylic Acid as a First-in-Class Low-Cytotoxic Nanomolar Metallo β-Lactamase Inhibitor.
Woo Shik ShinAlexander BergstromRobert A BonomoMichael W CrowderRamaiah MuthyalaYuk Yin ShamPublished in: ChemMedChem (2017)
VIM-2 is one of the most common carbapenem-hydrolyzing metallo β-lactamases (MBL) found in many drug-resistant Gram-negative bacterial strains. Currently, there is a lack of effective lead compounds with optimal therapeutic potential within our drug development pipeline. Here we report the discovery of 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid (3) as a first-in-class metallo β-lactamase inhibitor (MBLi) with a potent inhibition Ki of 13 nm against VIM-2 that corresponds to a remarkable 0.99 ligand efficiency. We further established that 3 can restore the antibiotic activity of amoxicillin against VIM-2-producing E. coli in a whole cell assay with an EC50 of 110 nm. The potential mode of binding of 3 from molecular modeling provided structural insights that could corroborate the observed changes in the biochemical activities. Finally, 3 possesses a low cytotoxicity (CC50 ) of 97 μm with a corresponding therapeutic index of 880, making it a promising lead candidate for further optimization in combination antibacterial therapy.
Keyphrases
- gram negative
- multidrug resistant
- drug resistant
- acinetobacter baumannii
- klebsiella pneumoniae
- high throughput
- escherichia coli
- small molecule
- photodynamic therapy
- single cell
- cell therapy
- neoadjuvant chemotherapy
- anti inflammatory
- squamous cell carcinoma
- risk assessment
- human health
- climate change
- binding protein
- radiation therapy
- dna binding
- cystic fibrosis
- mesenchymal stem cells
- wound healing